Table 3 Relationship between HbA1c and 3-month adverse clinical outcomes in AIS patients with and without diabetes

Non-DM

HbA1c (per 1% increase)

1.42 (0.88, 2.27) 0.149

1.23 (0.75, 2.03) 0.419

1.68 (0.92, 3.07) 0.092

HbA1c group

HbA1c (< 5.5%)

0.82 (0.53, 1.26) 0.360

0.84 (0.53, 1.33) 0.449

0.84 (0.49, 1.46) 0.542

HbA1c (5.5%-6.0%)

Ref

Ref

Ref

HbA1c (6.0%-6.5%)

1.02 (0.71, 1.45) 0.925

0.94 (0.65, 1.36) 0.733

1.03 (0.67, 1.60) 0.888

DM

HbA1c (per 1% increase)

1.01 (0.89, 1.15) 0.836

1.06 (0.93, 1.21) 0.374

1.14 (0.97, 1.35) 0.118

HbA1c group

HbA1c (< 6.0%)

1.91 (0.97, 3.77) 0.062

2.17 (1.07, 4.40) 0.032

2.27 (0.94, 5.50) 0.069

HbA1c (6.0%-6.5%)

Ref

Ref

Ref

HbA1c (6.5%-7.0%)

1.19 (0.69, 2.05) 0.540

1.32 (0.75, 2.33) 0.338

1.92 (0.95, 3.86) 0.069

HbA1c (≥ 7.0%)

1.11 (0.67, 1.86) 0.679

1.35 (0.79, 2.31) 0.276

1.70 (0.88, 3.31) 0.116